Skip to main content

Table 1 Baseline demographic data and clinical characteristics of patients included in the study

From: The effect of dobutamine in sepsis: a propensity score matched analysis

Covariate Original patients (before matching) Missing data (%)
Non-dobutamine group (N = 2165) Dobutamine group (N = 121) P value
Age (years) 66.63 ± 17.06 68.57 ± 16.44 0.222 0.0
Gender (Male), n (%) 1208 (55.8%) 74 (61.2%) 0.248 0.0
Height (cm) 168.76 ± 11.00 168.61 ± 9.68 0.883 0.0
Weight (kg) 82.65 ± 27.00 83.26 ± 21.95 0.808 0.0
BMI (kg/m [2]) 29.00 ± 9.00 29.13 ± 6.72 0.871 0.0
Temperature (℃) 37.71 ± 1.04 37.87 ± 1.11 0.108 0.4
MAP (mmHg) 51.63 ± 14.01 46.44 ± 15.51 0.000 0.0
HR (beats min−1) 112.71 ± 22.97 118.60 ± 23.46 0.006 0.0
RR (min−1) 30.23 ± 7.11 31.78 ± 8.00 0.020 0.0
SOFA score 7.22 ± 4.00 9.91 ± 3.73 0.000 0.0
SOFA-cardiovascular score 2.26 ± 1.45 3.23 ± 1.20 0.000 0.0
SAPS-I score 21.46 ± 5.68 24.86 ± 5.64 0.000 0.0
SAPS-II score 46.76 ± 16.66 56.59 ± 14.83 0.000 0.0
ECI 10.36 ± 7.91 11.06 ± 7.92 0.342 0.0
Norepinephrine dose (mg) 58.30 ± 82.56 79.89 ± 96.44 0.004 0.0
Norepinephrine use 1269 (58.6%) 110 (90.9%) 0.000 0.0
Urine volume (ml, 1st day) 1565.61 ± 1333.18 1083.63 ± 1005.80 0.000 1.0
Input volume (ml, 1st day) 8209.26 ± 6142.67 9471.47 ± 7166.17 0.069 4.3
Microbiology, n (%)
 Positive (%) 1719 (79.4%) 99 (81.8%) 0.521 0.0
 Negative 446 (20.6%) 22 (18.2%)
Interventions, n (%)
 Renal replacement use (1st day) 170 (7.9%) 15 (12.4%) 0.074 0.0
 Mechanical ventilation use (1st day) 1128 (52.1%) 95 (78.5%) 0.000 0.0
Comorbidities, n (%)
 Congestive heart failure 780 (36.0%) 75 (62.0%) 0.000 0.0
 Pulmonary circulation disease 168 (7.8%) 10 (8.3%) 0.840 0.0
 Renal failure 469 (21.7%) 23 (19.0%) 0.489 0.0
 Diabetes 676 (31.2%) 44 (36.4%) 0.236 0.0
 COPD 496 (22.9%) 33 (27.3%) 0.268 0.0
 Coagulopathy 614 (28.4%) 53 (43.8%) 0.000 0.0
 Fluid electrolyte disorder 1204 (55.6%) 66 (54.5%) 0.818 0.0
Admission type, n (%)
 Emergency 2106 (97.3%) 113 (93.4%) 0.014 0.0
 Elective 59 (2.7%) 8 (6.6%) 0.0
Sepsis type, n (%)
 Sepsis 451 (20.8%) 7 (5.8%) 0.000 0.0
 Severe sepsis 896 (41.4%) 50 (41.3%) 0.0
 Septic shock 818 (37.8%) 64 (52.9%) 0.0
Laboratory Tests
 Lactate (mmol/L) 2.59 ± 2.19 3.50 ± 2.86 0.001 48.4
 Glucose-min 106.90 ± 38.77 108.06 ± 48.17 0.753 0.5
 Glucose-max 190.70 ± 94.38 227.50 ± 93.32 0.000 0.5
  1. Data are mean ± SD, median (interquartile) or n (%). SOFA Sequential Organ Failure Assessment, ranging from 0 to 24, with higher scores indicating a greater degree of organ failure; ECI Elixhauser comorbidity index, and we used the modified vanWalraven Elixhauser comorbidity score in our study, which consists of 30 comorbidity diseases, range from − 19 to 89 points, with higher scores indicating a greater risk of hospital mortality, MAP mean arterial pressure; HR: heart rate, RR respiratory rate, SAPS-I simplified acute physiologic score-I, SAPS-II simplified acute physiologic score-II, ICU intensive care unit, COPD chronic obstructive pulmonary disease. The definitions and diagnositic criteria for sepsis, severe sepsis and septic shock were made according to the Surviving Sepsis Campaign Guidelines [1, 13, 14]